In this article, we will discuss: 11 Best Day Trading Stocks to Buy Now.
In a recent appearance on CNBC, a member of the channel’s Halftime Report’s Investment Committee, Joseph Terranova, discussed the ongoing volatility in the stock market stemming from the military operations in Iran. The volatility was clear on Thursday following Iran’s first attacks on oil tankers so far in the conflict. As oil prices surged due to the Hormuz Strait being blocked, the Chicago Volatility Index surged by 13% on Thursday before closing at 24.92. Terranova commented on the overall volatility in the market and the impact on financial firms:
“If you are a hedge fund. . .if you’re institutional, you’re focused on alpha generation. This has become a horrible environment to do that. And less is more. And you are participating less. The extreme volatility driven by whether it’s a tweet or a headline, that’s a very punitive environment to be in. So, the people in that world, that I speak to, they are providing less liquidity, they are stepping back. They are awaiting some degree of certainty involving the oil market.”
Our Methodology
To curate our list of the 11 best day trading stocks to buy now we used a screener to narrow down stocks with an average daily trading volume of at least 1 million shares and average weekly trading range of over 10%. The stocks were then ranked by the number of hedge funds that had held them during Q4 2025.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 498.7% since May 2014, beating its benchmark by 303 percentage points (see more details here).
11 Best Day Trading to Stocks Buy Now
11. Ondas Inc. (NASDAQ:ONDS)
Number of Hedge Fund Holdings: 29
Financial firm Needham discussed Ondas Inc. (NASDAQ:ONDS)’s shares on March 10th. It reiterated a Buy rating and a $17 share price target. On the same day, Stifel also commented on the stock as it reiterated a Buy rating and a $18 share price target. The coverage came after Ondas Inc.’s preliminary fourth-quarter and full-year earnings report. The results saw the firm post expected $29.1 million to $30.1 million in revenue and $20.9 million and $20.4 in net loss for the quarter and $49.7 million to $50.7 million in revenue and net loss of $53.3 million and $52.8 million for the full year.
Ondas Inc. also announced earlier this month that it had secured an operational order for its demining business from Israel. The order came to its subsidiary 4M Defense and will be worth $30 million over its full life. Ondas Inc. is also currently in the process of acquiring defense contractor Mistral for $175 million. The deal is expected to close in the second quarter of 2026.
Ondas Inc. is an American company that provides connectivity software, drones, base stations, and other products. It is headquartered in West Palm Beach, Florida.
10. StubHub Holdings, Inc. (NYSE:STUB)
Number of Hedge Fund Holdings: 31
Oppenheimer reduced StubHub Holdings, Inc. (NYSE:STUB)’s share price target on March 5th. It cut the target price from $20 to $12 and kept an Outperform rating, as per The Fly. The financial firm explained that StubHub Holdings, Inc.’s stock had potentially seen significant interest evaporate. Oppenheimer’s coverage came after the ticket company had reported its earnings for the fourth quarter and full year 2025.
The results saw StubHub Holdings, Inc. post $449 million in revenue and $1.56 in net loss per share. Analysts, on the other hand, had expected the firm to post $485 million in revenue and $1 in loss per share. A major reason behind StubHub Holdings, Inc.’s weakness was the crackdown on ticket resales as legislators in the US and the UK sought to limit the ticket resale prices. The shares had jumped by 11% in January even as law firms sought to recruit investors for a suit against the company for allegedly misrepresenting facts in its registration statement.
StubHub Holdings, Inc. is an online marketplace that enables users to buy and sell tickets. It is headquartered in New York, New York.
9. Sable Offshore Corp. (NYSE:SOC)
Number of Hedge Fund Holdings: 35
Financial firm Benchmark downgraded Sable Offshore Corp. (NYSE:SOC)’s shares to Hold from Buy on March 5th, according to The Fly. The financial firm discussed the oil company’s legal turmoils as it outlined that even though the firm’s California pipeline had been reclassified, it will continue to be challenged in court. Benchmark added that even though it expected the federal reclassification to be a positive development, the resulting circumstances were less than optimal.
Sable Offshore Corp.’s California prospects received a fresh boost on March 12th after it was reported that President Trump plans to use emergency powers for its California oil project. The back and forth between the federal and state governments is for the firm’s Santa Ynez unit, with the federal government seeking to remove regulatory concerns for the project. Sable Offshore Corp.’s shares fell in January after California’s Attorney General sued to stop the federal government from taking over two oil pipelines.
Sable Offshore Corp. is an independent oil and gas company with 16 leases all over the US. The firm is headquartered in Houston, Texas.
8. Applied Optoelectronics, Inc. (NASDAQ:AAOI)
Number of Hedge Fund Holdings: 36
Financial firm Rosenblatt discussed Applied Optoelectronics, Inc. (NASDAQ:AAOI)’s shares on March 9th, according to The Fly. It raised the firm’s share price target to $140 from $125 and kept a Buy rating on the stock. The coverage came after Applied Optoelectronics, Inc. announced a $200 million deal to supply 1.6T transceivers, and the financial firm speculated that the customer could be data center giant Oracle. Rosenblatt added that it expects Oracle and Microsoft to become the firm’s customers in the future.
On February 26th, Applied Optoelectronics, Inc. reported its earnings for the fourth quarter and full year 2025. The results saw the firm post $134 million in revenue for the fourth quarter and $455 million in revenue for the full year. However, Applied Optoelectronics, Inc. also reported a $2 million loss for the fourth quarter and a $38 million loss for the full year. As for the first quarter, Applied Optoelectronics, Inc. guided between $150 million to $165 million in revenue.
Applied Optoelectronics, Inc. is an optical communications products designer and manufacturer. Its products are used in the data center, telecommunications, and other industries.
7. nLIGHT, Inc. (NASDAQ:LASR)
Number of Hedge Fund Holdings: 36
Financial firm Baird initiated coverage on nLIGHT, Inc. (NASDAQ:LASR)’s shares on March 4th. It set a $95 share price target and an Outperform rating, according to The Fly. Baird pointed toward nLIGHT, Inc.’s vertical integration and technology stack, which it believes can help the firm grow its business as it makes and sells a wide range of products from chips to high-power lasers.
nLIGHT, Inc. reported its earnings for the fourth quarter and full year 2025 on February 26th. The results saw the firm post $261 million in revenue and $23 million in net loss for the full year. For the quarter, nLIGHT, Inc. posted $81 million in revenue and $4 million in net loss. The firm’s quarterly revenue marked a 71% annual growth, while its full-year revenue marked a 31% annual growth. As part of his prepared remarks, the firm’s CEO outlined that his company had benefited from the strength in the aerospace and defense market.
nLIGHT, Inc. designs and sells chips and lasers used in the aerospace, industrial, microfabrication, and other markets. The firm is headquartered in Camas, Washington.
6. Tango Therapeutics Inc. (NASDAQ:TNGX)
Number of Hedge Fund Holdings: 36
Financial firm Mizuho raised its share price target for Tango Therapeutics Inc. (NASDAQ:TNGX) on March 11th. It slightly adjusted the target to $20 from $19 and kept an Outperform rating on the stock. Mizuho’s coverage came after the precision oncology company reported its earnings for the fourth quarter and full year 2025. The results saw Tango Therapeutics Inc. post $343 million in cash and outline that it expected to have runway beyond 2028. The firm also outlined that it was on track to start a study for pancreatic cancer treatment and added that it had entered into an agreement for evaluating a molecular glue in a clinical trial.
Wedbush also discussed Tango Therapeutics Inc.’s shares in March. It raised the share price target to $19 from $15 and kept an Outperform rating on the stock. The financial firm outlined that it expected Tango Therapeutics Inc.’s vopimetostat treatment for pancreatic cancer to enter its first major study in 2026.
Tango Therapeutics Inc. is a biotechnology company focusing on cancer treatments. It is headquartered in Boston, Massachusetts.
5. Hims & Hers Health, Inc. (NYSE:HIMS)
Number of Hedge Fund Holdings: 39
Investment bank Barclays discussed Hims & Hers Health, Inc.’s shares on March 11th. It raised the share price target to $29 from $25 and kept an Overweight rating on the stock. Barclays commented that the fact that Hims & Hers Health, Inc.’s shares had performed well after its agreement with Novo Nordisk indicated that the firm’s legal woes were behind it. Barclays added that the market appeared to be underestimating the opportunities for new products from new products.
Barclays coverage came after Novo Nordisk announced that it had decided to drop its legal action against Hims & Hers Health, Inc. for what the healthcare company dubbed an illegal compound dispute. Novo had taken the action after Hims & Hers Health, Inc. had announced that it would sell its own weight loss pill. The development came after the pair had ended their partnership last year to provide discounted weight loss shots to Hims & Hers Health, Inc.’s customers.
Hims & Hers Health, Inc. is a health platform that offers prescription and non-prescription products to consumers. The firm is headquartered in San Francisco, California.
4. Figure Technology Solutions, Inc. (NASDAQ:FIGR)
Number of Hedge Fund Holdings: 40
Financial firm Mizuho discussed technology company Figure Technology Solutions, Inc. (NASDAQ:FIGR)’s shares on March 10th. It lowered the share price target to $55 from $64 and kept an Outperform rating on the stock. As part of its coverage, the financial firm outlined that it continued to be optimistic about Figure Technology Solutions, Inc.’s long term growth potential. The technology firm partnered up with BitGo Holdings in February to complete the world’s first fully on-chain equity trades through which shares were issued, traded, and settled through blockchain technology.
Investment firm Piper Sandler discussed Figure Technology Solutions, Inc.’s shares in January. It raised the price target to $75 from $55 and kept an Overweight rating on the stock. The coverage came after the technology company reported its earnings for the fourth quarter of 2025. The results saw Figure Technology Solutions, Inc.’s total client loans jump to $2.7 billion from $1.17 billion from the year-ago quarter.
Figure Technology Solutions, Inc. is a technology company that provides a blockchain-based market platform for trading and investing. It is headquartered in Reno, Nevada.
3. Dyne Therapeutics Inc. (NASDAQ:DYN)
Number of Hedge Fund Holdings: 61
Earlier this month, Dyne Therapeutics Inc. (NASDAQ:DYN) announced important updates for its DMD and DM1 programs. The firm revealed that it planned to submit an accelerated application for its DMD drug to target a launch in the first quarter of 2027. Dyne Therapeutics Inc. added that for DM1, it had completed enrollment for a Phase 1/2 trial. On March 8th, the firm revealed that it had started a Phase 3 trial of the drug DYNE-101 for the disease, and on the same day, Dyne Therapeutics Inc. revealed that its Phase 1/2 DELIVER trial for DMD had shown results when it came to baseline in lung function and other metrics.
Investment bank Morgan Stanley discussed the pharmaceutical company’s shares on March 3rd. It reduced the share price target to $47 from $50 and kept an Overweight rating, according to The Fly. Morgan Stanley outlined that Dyne Therapeutics Inc.’s programs for Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1) were on track, and 2026 could see the firm execute on its key programs.
Dyne Therapeutics Inc. is a biotechnology company focusing on developing treatments for neuromuscular diseases. It is headquartered in Waltham, Massachusetts.
2. Mineralys Therapeutics Inc. (NASDAQ:MLYS)
Number of Hedge Fund Holdings: 88
Biopharmaceutical company Mineralys Therapeutics Inc. (NASDAQ:MLYS) scored a win on March 9th when it announced that the Food and Drug Administration (FDA) had accepted its New Drug Application (NDA) for its lorundrostat drug to treat hypertension when combined with other hypertensive drugs. As part of the release, the firm’s CEO outlined that while the drug’s Explore-OSA trial did not show a reduction in the apnea-hypopnea index (AHI), the drug’s safety profile and its impact on blood pressure were nevertheless meaningful.
The FDA’s NDA approval came after Mineralys Therapeutics Inc. announced in January that it had submitted the application. In December 2025, Bank of America raised the firm’s share price target to $46 from $43 and kept a Buy rating on the stock. The coverage came after Mineralys Therapeutics Inc.’s earnings report for the third quarter of 2025, which saw the firm confirm that it had a cash runway up to 2027.
Mineralys Therapeutics Inc. is a biotechnology company that is focused on developing drugs for ailments stemming from aldosterone dysregulation. It is headquartered in Radnor, Pennsylvania.
1. Lumentum Holdings Inc. (NASDAQ:LITE)
Number of Hedge Fund Holdings: 97
Investment bank Barclays discussed photonics and optical products manufacturer Lumentum Holdings Inc. (NASDAQ:LITE)’s shares on March 3rd. It raised the share price target to $750 from $475 and kept an Equal-Weight rating on the shares. The coverage came a month after Lumentum Holdings Inc. reported its earnings for the second fiscal quarter of 2026. The results saw the firm report $665 million in revenue and $143 million in non-GAAP net income.
On the same day, Rosenblatt also discussed Lumentum Holdings Inc.’s shares. It raised the share price target to $900 from $580 and kept a Buy rating on the stock. Rosenblatt pointed out that the firm will benefit from AI chip giant NVIDIA’s decision to invest $2 billion in it and to secure future capacity for optical products. Like the two financial firms, investment bank Morgan Stanley is also optimistic about Lumentum Holdings Inc.. It raised the price target to $520 from $420 and kept an Equal Weight rating on the shares.
Lumentum Holdings Inc. is an American company that makes and sells optical and photonic products used in computing and other applications. It is headquartered in San Jose, California.
READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.
.
